Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.78 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.78 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.78 |
| ▸ | KLK1 | P06870 | 1/20 | 0.65 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595681 | 1.00 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DKLK1 | |
| SCHEMBL1135194 | 0.91 | CA1 (0.64) | PDE4APDE4BPDE4CPDE4DKLK1 | |
| SCHEMBL3472792 | 0.90 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DKLK1 | |
| SCHEMBL2531139 | 0.88 | PDE4B (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13470651 | 0.88 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DKLK1 | |
| SCHEMBL595898 | 0.86 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DKLK1 | |
| SCHEMBL5583471 | 0.86 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DKLK1 | |
| SCHEMBL596054 | 0.85 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DKLK1 | |
| SCHEMBL3475067 | 0.85 | KLK1 (0.69) | PDE4APDE4BPDE4CPDE4DKLK1 | |
| SCHEMBL5583385 | 0.85 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | PDE4A 4397/4885PDE4B 4444/4885PDE4C 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.